Altimmune (NASDAQ:ALT) Shares Down 5.4% – What’s Next?

Altimmune, Inc. (NASDAQ:ALT)’s share price fell 5.4% during trading on Monday . The company traded as low as $7.13 and last traded at $7.20. 623,008 shares were traded during trading, a decline of 84% from the average session volume of 3,857,509 shares. The stock had previously closed at $7.61.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ALT. B. Riley restated a “buy” rating and set a $20.00 price objective on shares of Altimmune in a research note on Monday, August 12th. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research note on Thursday, November 14th. UBS Group started coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. Finally, Evercore ISI upgraded shares of Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Altimmune Price Performance

The stock has a market cap of $531.27 million, a price-to-earnings ratio of -4.82 and a beta of 0.09. The business’s 50-day simple moving average is $7.05 and its two-hundred day simple moving average is $6.91.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million for the quarter. During the same quarter last year, the firm posted ($0.39) EPS. Equities research analysts forecast that Altimmune, Inc. will post -1.36 earnings per share for the current year.

Institutional Investors Weigh In On Altimmune

Several hedge funds and other institutional investors have recently bought and sold shares of ALT. Larson Financial Group LLC bought a new stake in shares of Altimmune during the third quarter worth about $31,000. CANADA LIFE ASSURANCE Co purchased a new position in Altimmune in the first quarter valued at about $44,000. Horizon Wealth Management LLC purchased a new position in Altimmune in the second quarter valued at about $66,000. PFG Investments LLC purchased a new position in Altimmune in the second quarter valued at about $67,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Altimmune during the 2nd quarter valued at approximately $70,000. 78.05% of the stock is owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.